Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Cardiomyopathy" and "Society guideline links: Immunoglobulin light chain (AL) amyloidosis" and "Society guideline links: Heart failure in adults".)
International
●American Society of Nuclear Cardiology (ASNC)/American Heart Association (AHA)/American Society of Echocardiography (ASE)/European Association of Nuclear Medicine (EANM)/Heart Failure Society of America (HFSA)/International Society of Amyloidosis (ISA)/Society for Cardiovascular Magnetic Resonance (SCMR)/Society of Nuclear Medicine and Molecular Imaging (SNMMI): Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis – Part 1 of 2: Evidence base and standardized methods of imaging (2021)
●ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI: Expert consensus recommendations for multimodality imaging in cardiac amyloidosis – Part 2 of 2: Diagnostic criteria and appropriate utilization (2021)
●Amyloidosis Research Consortium (ARC): Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis (2019)
●ARC: Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy (2019)
●Heart Rhythm Society (HRS): Expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy (2019)
●Society for Cardiovascular Magnetic Resonance (SCMR): Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume – A consensus statement (2017)
Canada
●Canadian Cardiovascular Society (CCS)/Canadian Heart Failure Society (CHFS): Heart failure guidelines – Clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis (2020)
●CCS/CHFS: Joint position statement on the evaluation and management of patients with cardiac amyloidosis (2020)
United States
●American Society of Nuclear Cardiology (ASNC)/American Heart Association (AHA)/American Society of Echocardiography (ASE)/European Association of Nuclear Medicine (EANM)/Heart Failure Society of America (HFSA)/International Society of Amyloidosis (ISA)/Society for Cardiovascular Magnetic Resonance (SCMR)/Society of Nuclear Medicine and Molecular Imaging (SNMMI): Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis – Part 1 of 2: Evidence base and standardized methods of imaging (2021)
●ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI: Expert consensus recommendations for multimodality imaging in cardiac amyloidosis – Part 2 of 2: Diagnostic criteria and appropriate utilization (2021)
●AHA: A scientific statement on cardiac amyloidosis – Evolving diagnosis and management (2020)
●ASNC: Cardiac amyloidosis practice points – 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis (2019)
●ASNC and EANM: Cardiac amyloidosis practice points – 99mTechnetium3,3-diphosphono1,2-propanodicarboxylic acid (DPD) and 99mtechnetium hydroxymethylene diphosphonate (HMDP) imaging for transthyretin cardiac amyloidosis (2019)
●ASNC: Imaging guidelines for nuclear cardiology procedures (2017)
Europe
●American Society of Nuclear Cardiology (ASNC)/American Heart Association (AHA)/American Society of Echocardiography (ASE)/European Association of Nuclear Medicine (EANM)/Heart Failure Society of America (HFSA)/International Society of Amyloidosis (ISA)/Society for Cardiovascular Magnetic Resonance (SCMR)/Society of Nuclear Medicine and Molecular Imaging (SNMMI): Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis – Part 1 of 2: Evidence base and standardized methods of imaging (2021)
●ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI: Expert consensus recommendations for multimodality imaging in cardiac amyloidosis – Part 2 of 2: Diagnostic criteria and appropriate utilization (2021)
●European Society of Cardiology (ESC): Guidelines for the diagnosis and treatment of acute and chronic heart failure (2021)
●ESC: Position statement for the diagnosis and treatment of cardiac amyloidosis (2021)
●ASNC and EANM: Cardiac amyloidosis practice points – 99mTechnetium3,3-diphosphono1,2-propanodicarboxylic acid (DPD) and 99mtechnetium hydroxymethylene diphosphonate (HMDP) imaging for transthyretin cardiac amyloidosis (2019)
●ESC: Clinical practice update on heart failure – Pharmacotherapy, procedures, devices and patient management (2019)
●European Network for TTR-FAP (ATTReuNET): Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis (2016)
Japan
●[In English] Japanese Circulation Society (JCS): Guideline on diagnosis and treatment of cardiac amyloidosis (2020)
●[In Japanese] JCS: Guideline on diagnosis and treatment of cardiac amyloidosis (2020)
